BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 21252717)

  • 1. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer.
    Sirera R; Bremnes RM; Cabrera A; Jantus-Lewintre E; Sanmartín E; Blasco A; Del Pozo N; Rosell R; Guijarro R; Galbis J; Sánchez JJ; Camps C
    J Thorac Oncol; 2011 Feb; 6(2):286-90. PubMed ID: 21252717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification in the serum of the catalytic fraction of reverse telomerase: a useful prognostic factor in advanced non-small cell lung cancer.
    Camps C; Sirera R; Bremnes RM; Ródenas V; Blasco A; Safont MJ; Garde J; Juarez A; Caballero C; Sanchez JJ; Taron M; Rosell R
    Anticancer Res; 2006; 26(6C):4905-9. PubMed ID: 17214360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.
    Vinayanuwattikun C; Sriuranpong V; Tanasanvimon S; Chantranuwat P; Mutirangura A
    J Thorac Oncol; 2011 Nov; 6(11):1818-25. PubMed ID: 21964525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased human telomerase reverse transcriptase (hTERT) mRNA expression but not telomerase activity is related to survival in curatively resected non-small cell lung cancer.
    Metzger R; Vallbohmer D; Müller-Tidow C; Higashi H; Bollschweiler E; Warnecke-Eberz U; Brabender J; Baldus SE; Xi H; Berdel WE; Serve H; Hoelscher AH; Schneider PM
    Anticancer Res; 2009 Apr; 29(4):1157-62. PubMed ID: 19414359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
    Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP
    J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer.
    Paci M; Maramotti S; Bellesia E; Formisano D; Albertazzi L; Ricchetti T; Ferrari G; Annessi V; Lasagni D; Carbonelli C; De Franco S; Brini M; Sgarbi G; Lodi R
    Lung Cancer; 2009 Apr; 64(1):92-7. PubMed ID: 18804892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detecting cell-free circulating hTERT mRNA in the plasma may identify a subset of nonsmall cell lung cancer patients.
    Pelosi G; Schianchi E; Dell'orto P; Veronesi G; Spaggiari L; Pasini F; Sozzi G; Brambilla E; Griso C; Viale G
    Virchows Arch; 2006 Jan; 448(1):7-15. PubMed ID: 16193293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer.
    Foss KM; Sima C; Ugolini D; Neri M; Allen KE; Weiss GJ
    J Thorac Oncol; 2011 Mar; 6(3):482-8. PubMed ID: 21258252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer.
    Miura N; Nakamura H; Sato R; Tsukamoto T; Harada T; Takahashi S; Adachi Y; Shomori K; Sano A; Kishimoto Y; Ito H; Hasegawa J; Shiota G
    Cancer Sci; 2006 Dec; 97(12):1366-73. PubMed ID: 17052260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.
    Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Piattoni S; Di Carlo L; Semeraro A; Darwish S; Tofanetti FR; Stocchi L; Mihaylova Z; Bellezza G; Del Sordo R; Daddi G; Crinò L; Tonato M
    J Thorac Oncol; 2008 Apr; 3(4):365-73. PubMed ID: 18379354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients.
    Powrózek T; Krawczyk P; Nicoś M; Kuźnar-Kamińska B; Batura-Gabryel H; Milanowski J
    Clin Transl Oncol; 2016 Apr; 18(4):398-404. PubMed ID: 26311076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and prognostic value of hTERT mRNA expression in patients with non-small-cell lung cancer.
    Zalewska-Ziob M; Dobija-Kubica K; Biernacki K; Adamek B; Kasperczyk J; Bruliński K; Ostrowska Z
    Acta Biochim Pol; 2017; 64(4):641-646. PubMed ID: 29141053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated lactic acid is a negative prognostic factor in metastatic lung cancer.
    Vlachostergios PJ; Oikonomou KG; Gibilaro E; Apergis G
    Cancer Biomark; 2015; 15(6):725-34. PubMed ID: 26406401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR array: uses in the detection of plasma EGFR mutations in non-small cell lung cancer patients.
    Yam I; Lam DC; Chan K; Chung-Man Ho J; Ip M; Lam WK; Chan TK; Chan V
    J Thorac Oncol; 2012 Jul; 7(7):1131-40. PubMed ID: 22610259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of free circulating DNA as a diagnostic marker in lung cancer.
    Sozzi G; Conte D; Leon M; Ciricione R; Roz L; Ratcliffe C; Roz E; Cirenei N; Bellomi M; Pelosi G; Pierotti MA; Pastorino U
    J Clin Oncol; 2003 Nov; 21(21):3902-8. PubMed ID: 14507943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer.
    van der Drift MA; Hol BE; Klaassen CH; Prinsen CF; van Aarssen YA; Donders R; van der Stappen JW; Dekhuijzen PN; van der Heijden HF; Thunnissen FB
    Lung Cancer; 2010 May; 68(2):283-7. PubMed ID: 19632736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiplex PCR-based detection of circulating tumor cells in lung cancer patients using CK19, PTHrP, and LUNX specific primers.
    Katseli A; Maragos H; Nezos A; Syrigos K; Koutsilieris M
    Clin Lung Cancer; 2013 Sep; 14(5):513-20. PubMed ID: 23810363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diagnostic and prognostic relevance of human telomerase reverse transcriptase mRNA expression detected in situ in patients with nonsmall cell lung carcinoma.
    Fujita Y; Fujikane T; Fujiuchi S; Nishigaki Y; Yamazaki Y; Nagase A; Shimizu T; Ohsaki Y; Kikuchi K
    Cancer; 2003 Sep; 98(5):1008-13. PubMed ID: 12942569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating free DNA concentration is an independent prognostic biomarker in lung cancer.
    Tissot C; Toffart AC; Villar S; Souquet PJ; Merle P; Moro-Sibilot D; Pérol M; Zavadil J; Brambilla C; Olivier M; Couraud S
    Eur Respir J; 2015 Dec; 46(6):1773-80. PubMed ID: 26493785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Circulating miRNA-17 and miRNA-222 Expression Profiles as Non-Invasive Biomarkers in Egyptian Patients with Non-Small-Cell Lung Cancer.
    Hetta HF; Zahran AM; El-Mahdy RI; Nabil EE; Esmaeel HM; Elkady OA; Elkady A; Mohareb DA; Mahmoud Mostafa M; John J
    Asian Pac J Cancer Prev; 2019 Jun; 20(6):1927-1933. PubMed ID: 31244320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.